Epocrates vs Medscape: cost, drug reference depth and interaction checking compared

For drug lookups alone, Medscape covers more ground for nothing. Its listing states prescribing information on more than 9,200 drugs against the 6,000-plus monographs Epocrates advertises in its free tier, and Medscape throws in more than 450 specialty calculators and free CME on top. Judged purely on what you get without paying, Medscape wins on breadth and it is not close.

Epocrates wins on feel. Clinicians who prefer it almost always say the same thing: it is faster to get from opening the app to the number they needed, and the monograph layout is easier to scan mid-encounter. That is a real advantage even though it does not show up in a feature table, and it is why plenty of prescribers keep Epocrates as the muscle-memory app and Medscape as the one they open when they need a calculator or a CME credit.

The honest framing is that these are not competing on quality of drug data so much as on interface and business model. Both are maintained clinical references from established publishers. If you want one app, install both, use each for a fortnight, and keep whichever one you reach for without thinking. They cost nothing to test, which is the unusual luxury in this category. If you want the paid tier of either, our breakdown of what Epocrates actually costs covers what the upgrade includes.

That depends entirely on whether you want the disease reference, because the drug reference is already free. This is the single most misunderstood thing about the product. People assume epocrates+ unlocks better drug data, and it does not. The free registered tier carries the monographs, the pill identifier and the interaction checker. The $179.99 a year buys disease content with differential diagnosis support, lab value interpretation and the dosing calculators.

So run the test that way. If you are a prescriber who mostly needs to check a drug, a dose and an interaction, the free tier is the product and the upgrade is optional. If you are in a role where you regularly work a differential or interpret an unfamiliar lab result, and you do not already have UpToDate or a similar reference through your employer, the paid tier starts to earn its keep.

One thing worth checking before you pay: whether your hospital, group or medical library already licenses a clinical reference. A large share of US clinicians pay personally for access their organization already provides. The same trap applies across this category, which is why our Epocrates and Lexicomp comparison and the Epocrates alternatives page both lead with the same advice.

No, and the App Store listing is unusually clear about it: the app is free and shows no in-app purchases at all. There is no premium tier, no upgrade prompt and no feature gate. The drug reference, interaction checker, pill identifier, calculators, clinical news and CME are all available once you register.

It pays for itself through advertising, including sponsored content aimed at a clinical audience, and WebMD Health Corporation has run it that way for years. Clinicians differ on how much that bothers them. Some find promotional material next to reference content genuinely distracting; others barely register it. What matters for a buying decision is that there is no hidden fee waiting later, which is not something you can say about most tools in this category.

For physicians, the practical answer is whichever one you will actually open under time pressure, with Medscape the better value if you are not paying for anything and Epocrates the faster interface for pure drug lookup. Physicians who need graded, defensible recommendations are asking a different question, and that is the UpToDate conversation rather than this one. We compare that lane in UpToDate versus Medscape.

For nurses and advanced practice providers, Medscape tends to be the stronger free pick, largely because of the calculators and the free CME with MOC points, which map onto real recertification requirements. Nurses who need drug administration detail, IV compatibility and formulation specifics often end up wanting a deeper drug database than either app provides, which is where Lexidrug and Micromedex come in, at institutional prices.

For pharmacists, neither app is really the working tool. Pharmacy practice leans on the depth in Lexidrug or Micromedex, and both of those are almost always licensed by the employer. If you are evaluating that tier, our Lexicomp alternatives page lays out what the depth actually costs.

Yes, in the sense that matters: it is a maintained commercial drug reference from an established healthcare company, athenahealth, and it has been in clinical use for more than two decades. Its monograph content is compiled from the drug labeling and clinical pharmacology literature, and it is updated on an ongoing basis. Clinicians use it at the point of care every day without incident.

The caution is the one that applies to every reference app, including this site: a reference tells you what is generally true about a drug, not what is true about the patient in front of you. Renal function, hepatic function, age, pregnancy status, the rest of the medication list and the indication all change the answer. Class-level information is a starting point for a clinical judgment, and the current labeling remains the authority when the two disagree.

One practical limit worth knowing is the 30-medication cap on the free interaction checker. For most encounters that is irrelevant. For a genuinely polypharmacy patient on a long-term care list, it is a real ceiling, and it is exactly the population where interaction checking matters most.

Both wait to be asked. To catch a problem with the script in front of you, you have to remember to run the interaction check, then remember to check the contraindication, then think about the renal dose, then consider whether a safer agent exists. Four separate questions, four separate lookups, in a clinic already running behind. The checks that get skipped are almost never the ones a clinician decided to skip. They are the ones nobody thought to run.

Prescriber.io collapses that into one step. Enter the drug or the scenario and it checks interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments and suggests guideline-based alternatives, together, with sources cited on each flag. It is decision support for licensed clinicians, not autonomous prescribing: you review every flag, verify it against official sources, and sign. It sits alongside Epocrates or Medscape rather than replacing either, because looking a drug up and checking a decision are different jobs.